Paris, France – March 10, 2023
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today announces that its management team will attend and take part in 1-on-1 meetings with potential business partners at the following meetings:
Enterome’s CEO, Pierre Belichard, will present an overview of the Company and take part in 1-on-1 meetings with potential investors at the following conferences:
Contacts
ENTEROME | MEDIA RELATIONS |
Guillaume Bayre Head of External Communications Tel; +33 (0)1 76 21 58 15 communication@enterome.com |
Sylvie Berrebi / Mark Swallow / David Dible MEDiSTRAVA Consulting Tel. +44 (0) 203 928 6900 enterome@medistrava.com |
About Enterome
Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, allowing it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Its first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones, or cytokines.
The company’s two pipelines of drug candidates include:
Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €116 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships.
For more information, please visit the company’s website at: www.enterome.com
NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer…
HOUSTON, May 30, 2025 /PRNewswire/ -- Danziger & De Llano, LLP, a Texas-based law firm with…
Lumea and AIxMed team up to bring AI driven urine cytology to Lumea's platform, targeting…
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 30,…
WASHINGTON, May 30, 2025 /PRNewswire/ -- The National Hispanic Health Foundation (NHHF), formerly part of the…
BOSTON, May 30, 2025 /PRNewswire/ -- Velsera announces that its clinical Knowledgebase is powering the interpretation…